VAT Trap Blog

Reducing saturated fat intake is known to lower “bad” cholesterol (LDL-C) and reduce heart disease risk, but responses vary widely between individuals. Research shows that genetics strongly influence how much LDL rises when people eat foods like butter, cheese, or fatty meats compared with unsaturated fats such as olive oil, nuts, and oily fish. Even on the same diet, LDL responses can differ by up to 1 mmol/L, reflecting genetic differences in intestinal cholesterol absorpti

One of the greatest challenges in the online world is investigator bias. Any “expert” with a strong conviction — whether pro- or anti-statin — can easily find studies that appear to confirm their view. The internet is full of such cherry-picked data. When presented with confident authority, this can sound utterly convincing to a lay audience. The reality is that true medical understanding does not come from one paper, one YouTube video, or one self-proclaimed authority.

Santa’s famous belly is festive, but it highlights an important metabolic lesson: WHERE fat is stored matters more than how it looks. Visceral fat, hidden deep around the organs, drives inflammation and cardiometabolic risk — unlike softer, subcutaneous fat. Understanding this difference is key to real metabolic health.

The most effective path to reducing visceral fat with the help of GLP-1 mimetic is not just to “eat less.” It’s to build more muscle, eat smarter, and track your progress. In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.

A coronary stent treats a narrowed artery, not the biology that caused it. Insulin resistance driven by visceral fat promotes inflammation and abnormal healing, increasing restenosis risk. Diabetes is the end stage, but waist size often reveals risk much earlier — making metabolic health central to long-term outcomes after stenting.

GLP-1 drugs seem paradoxical: they enhance insulin action yet shrink dangerous belly fat. The explanation lies in restoring normal insulin timing, reducing chronic insulin exposure, and reversing fat “spillover” from liver to abdomen. Real patient cases show rapid visceral fat loss alongside smoother glucose profiles and lower cardiovascular risk.

The keto and Atkins diets have profound effects on hepatic lipid metabolism, and hence on LDL cholesterol handling. Let’s unpack this carefully through the lens of the endogenous cholesterol pathway.

Epigenetics is the molecular bridge between lifestyle and disease. It explains why two people eating the same meal can have very different glucose spikes, and why decades of stress or sleep loss can push one individual towards metabolic syndrome while another remains resilient.

Raised visceral fat quietly disrupts thyroid chemistry, increasing reverse T3 and lowering active T3 inside tissues. This pushes the body into metabolic “conservation mode” — slowing energy, mood and fat loss despite normal blood tests. Reducing VAT gradually restores healthy thyroid activation and metabolic resilience.

Adequate protein and resistance training are essential for healthy ageing and reducing visceral fat. As we grow older, muscles become less responsive, making higher protein intake vital to preserve strength, metabolism, and independence. Building and feeding muscle is the most effective way to improve insulin sensitivity, raise metabolic rate, and burn harmful VAT.

Patients often ask about home monitoring tools — ECG devices, blood pressure monitors, glucose apps. We now also encourage people to track their waistline and visceral fat, using body composition scales alongside more traditional equipment. To support this, I have created a page of recommended home gadgets that can help patients take greater ownership of their health — a vital step towards a more proactive, prevention-focused model of care, guided by their clinical and educat

The most effective path to reducing visceral fat without medication is not just to “eat less.” It’s to build more muscle, eat smarter, and track your progress. In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.

Traditional health improvement plans assume everyone responds the same way. Real life tells us otherwise. N-of-1 explains how to use a personalised, precision-medicine approach to reduce visceral fat, stabilise metabolism and rebuild long-term health. Through weekly reflections, practical tools and small self-experiments, the book guides you to uncover what truly works for you — not for the average patient, but for your own unique physiology.

At SCVC we use low dose CT to measure visceral adipose tissue (VAT). With a radiation dose of 1mSv – equivalent to 1/4 of the dose used in a mammogram. The test determines what proportion of an expanded waistline is visceral (metabolically dangerous) versus subcutaneous (metabolically benign) fat. When combined with other anthropometrics such as weight, height, waist we use AI to calculate a metabolically healthy target waist and weight to aim for. A example of a repeat scan

Some small studies show lower T3 inside fat tissue in people with obesity. This doesn’t mean systemic hypothyroidism — it simply suggests inflammation may reduce local T3 activation. Raised visceral fat quietly disrupts thyroid chemistry, increasing reverse T3 and lowering active T3 inside tissues.

Semaglutide’s cardiovascular benefits extend beyond weight loss — it powerfully reduces visceral adipose tissue (VAT), the internal fat that drives inflammation, insulin resistance and small dense LDL. At SCVC, our GLP-1 programme targets VAT directly using personalised VAT scans and flexible dosing to improve long-term heart health.

At Surrey Cardiovascular Clinic, we have seen a pattern: some people whose blood sugar (HbA₁c) is technically “normal” are quietly drifting towards diabetes. Their blood tests look fine — but their day-to-day glucose readings tell another story.

The keto and Atkins diets have profound effects on hepatic lipid metabolism, and hence on LDL cholesterol handling. Let’s unpack this carefully through the lens of the endogenous cholesterol pathway.

MASLD is a silent but important marker of metabolic health and another consequence of raised Visceral Adipose Tissue (VAT). Although often discovered by chance, it carries significant implications for both liver and cardiovascular wellbeing. Through caloric restriction, physical activity, improved nutrition, and early intervention, MASLD can usualy be stabilised or reversed — protecting not just the liver, but the heart as well.

Small dense LDL (sdLDL) is the most harmful form of “bad cholesterol.” It forms when the liver overproduces VLDL — often driven by visceral fat and high insulin levels. Visceral fat sits deep around the organs and feeds directly into the liver, causing early metabolic disruption long before blood tests detect it.